Ghaziabad Online

Inflammatory Bowel Disease Market in 7MM is expected to witness a major change in the study period 2019-2032 | Key Companies- Genentech, AbbVie, Arena Pharmaceuticals, and Many Others

 Breaking News
  • No posts were found

Inflammatory Bowel Disease Market in 7MM is expected to witness a major change in the study period 2019-2032 | Key Companies- Genentech, AbbVie, Arena Pharmaceuticals, and Many Others

September 27
22:41 2022
Inflammatory Bowel Disease Market in 7MM is expected to witness a major change in the study period 2019-2032 | Key Companies- Genentech, AbbVie, Arena Pharmaceuticals, and Many Others

DelveInsight’s Inflammatory Bowel Disease Market Insights report proffers a detailed comprehension of Inflammatory Bowel Disease market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Inflammatory Bowel Disease market size from 2018 to 2033 segmented into APAC region.

 

Increasing cases of Inflammatory Bowel Disease (IBD) in various regions lead to increased demand for advanced diagnostic and treatment in the Inflammatory Bowel Disease market, which in turn contribute to the growth of the market. Also, there are different factors contributing to higher diagnosis rates such as higher disease burden of IBD, major advances both in understanding disease pathogenesis and the developing newer diagnostic and therapeutic agents.

 

In addition to the above-increasing awareness among physicians and better diagnostic modalities picking up UC early in the disease course and improvement in access to healthcare systems, more widely available diagnostic tools, and increased awareness on the part of both patients and physicians. 

 

“Key players such as Gilead Sciences, AbbVie, Arena Pharmaceuticals, Eli Lilly, and others are also investigating their candidates for IBD. The Inflammatory Bowel Disease market is anticipated to grow due to some other factors as well such as an increase in the patient pool, expected entry of emerging therapies, and others”

 

Some of the essential features of the Inflammatory Bowel Disease Market Report: 

  • According to DelveInsight, the Inflammatory Bowel Disease Market in 7MM is expected to witness a major change in the study period 2019-2032
  • Major pharmaceutical Inflammatory Bowel Disease companies such as Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill BiopharmaPfizer, and others are reported to bring a significant shift in the Inflammatory Bowel Disease market 
  • The Inflammatory Bowel Disease emerging therapies that are expected to launch in the forecast period include Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104, Xeljanz  and others.
  • Of the Inflammatory Bowel Disease emerging therapies Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the treatment market, during the forecast period. Alofisel is recently approved in Japan in 2021.

 

For further information on market impact by therapies, download the Inflammatory Bowel Disease market sample at Inflammatory Bowel Disease Market Size

 

Inflammatory Bowel Disease Overview

Like any other part of the body, the digestive system and its organs are affected by different ailments, Inflammatory Bowel Disease (IBD) being one of them. Inflammatory Bowel Disease (IBD) is an umbrella term used to describe disorders that involve chronic inflammation of any part of the digestive tract.

The inflammation in the digestive tract affects its normal functioning and hampers the nutrient uptake by the body. It is a chronic condition, which means it lasts a long time or constantly comes and goes. There are two types of Inflammatory Bowel Disease: Crohn’s disease (CD) and Ulcerative colitis (UC).

 

The Inflammatory Bowel Disease Market report proffers epidemiological analysis for the study period 201_-3_ in the APAC Region segmented into

  • Number of Inflammatory Bowel Disease Prevalent Cases
  • Number of Inflammatory Bowel Disease Diagnosed Prevalent Cases
  • Inflammatory Bowel Disease Gender-specific Diagnosed Prevalent Cases
  • Inflammatory Bowel Disease Type-specific Diagnosed Prevalent Cases
  • Inflammatory Bowel Disease Severity-specific Diagnosed Prevalent Cases
  • Inflammatory Bowel Disease Age-specific Diagnosed Prevalent Cases

 

 

Inflammatory Bowel Disease Market Outlook

Inflammatory Bowel Disease is a disease that has no cure. Inflammatory Bowel Disease treatment aims to relieve symptoms, prevent other problems and future flare-ups, and possibly heal the inflamed intestines. Different Inflammatory Bowel Disease treatment approaches are followed for treating a patient. IBD Treatment involves medications as well as surgery and lifestyle changes.

Inflammatory Bowel Disease treatment aims to stop the abnormal inflammation, so intestinal tissue has a chance to heal. As it does, the symptoms of diarrhea and abdominal pain should be relieved. Once the symptoms are under control, medical treatment focuses on decreasing the frequency of flare-ups and maintaining remission. Doctors often take a step-by-step approach to use medications for inflammatory bowel disease. This way, the least harmful drugs or drugs that are only taken for a short period of time are used first. If they do not work, drugs from a higher step are used.

Some of the Inflammatory Bowel Disease marketed drugs include Entyvio (Vedolizumab) which is a gut-selective biologic developed by Takeda Pharmaceutical and Stelara (Ustekinumab) developed by Janssen Pharmaceuticals which is a prescription medicine approved for the treatment of adults 18 years and older with moderately to severely active Crohn’s disease and Ulcerative Colitis.

In addition to that, among the Inflammatory Bowel Disease emerging drugs are Etrolizumab (RG7413), which Roche and Genentech are developing, is a humanized IgG1 MAb targeting the beta-7 integrin subunit. The landmark study program includes more than 3,100 patients across six Phase III studies, Risankizumab (ABBV-066) which is an anti-IL-23 antibody being investigated by AbbVie and Boehringer Ingelheim. It is investigated to treat multiple inflammatory diseases, including Crohn’s disease and Ulcerative Colitis. Of the emerging therapies Skyrizi, Etrolizumab, Jyselica, and others are expected to enter the treatment market, during the forecast period. 

 

Discover more about therapy set to grab substantial Inflammatory Bowel Disease market share at Inflammatory Bowel Disease Market Landscape

 

 Inflammatory Bowel Disease Pipeline Therapies and Key Companies

  • Etrolizumab (RG7413): Hoffmann-La Roche, Genentech
  • Risankizumab (ABBV-066): Hoffmann-La Roche, Genentech
  • Rinvoq: AbbVie
  • Etrasimod (APD334): Arena Pharmaceuticals
  • Mirikizumab (LY3074828): Eli Lilly
  • Brazikumab: AstraZeneca
  • AJM300: Kissei Pharmaceutical, E A Pharma
  • Filgotinib: Gilead Sciences, Galapagos NV
  • Zeposia (Ozanimod; RPC1063): Celgene (Bristol-Myers Squibb)
  • Tremfya (Guselkumab): Janssen Pharmaceuticals
  • RHB-104: RedHill Biopharma

 

To know about more pipeline therapies covered in the report, visit Inflammatory Bowel Disease Emerging Therapies

 

Inflammatory Bowel Disease Market Dynamics

Market Drivers for Inflammatory Bowel Disease:

  • Involvement of digital technology for new-age Inflammatory Bowel Disease Treatment
  • Rich emerging pipeline of  Inflammatory Bowel Disease therapeutic area
  • Ample opportunity for new molecules with novel mechanisms of action
  • Potential for the development of more targeted therapeutics
  • Increasing prevalence of Crohn’s disease and Ulcerative Colitis globally
  • New biomarkers for Inflammatory Bowel Disease diagnosis
  • Rise in awareness regarding IBD

Market Barriers for Inflammatory Bowel Disease:

  • Entry of biosimilars in the Inflammatory Bowel Disease market
  • Insufficient knowledge of the disease
  • Significant drawbacks of currently existing therapeutic options in IBD treatment

 

Know which therapy is expected to score the touchdown first at Inflammatory Bowel Disease Market Landscape and Forecast

 

Scope of the Inflammatory Bowel Disease Market Insight Report

  • Study Period: 2019-2032
  • Coverage: APAC Region
  • Key IBD Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, Kissei Pharmaceutical, E A Pharma, Galapagos NV, Celgene (Bristol-Myers Squibb), RedHill Biopharma
  • Key Inflammatory Bowel Disease Pipeline Therapies: Etrolizumab (RG7413), Risankizumab (ABBV-066), Rinvoq, Etrasimod (APD334), Mirikizumab (LY3074828), Brazikumab, AJM300, Filgotinib, Zeposia (Ozanimod; RPC1063), Tremfya (Guselkumab), RHB-104
  • Inflammatory Bowel Disease Therapeutic Assessment:  Inflammatory Bowel Disease current marketed and emerging therapies
  • Inflammatory Bowel Disease Market Dynamics:  Inflammatory Bowel Disease market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs
  • KOL views
  • Analyst’s views
  • Inflammatory Bowel Disease Market Access and Reimbursement

 

 

Table of Content

1. Key Insights

2. Executive Summary of Inflammatory bowel disease

3. Competitive Intelligence Analysis for Inflammatory bowel disease

4. Inflammatory bowel disease: Market Overview at a Glance

5. Inflammatory bowel disease: Disease Background and Overview

6. Patient Journey

7. Inflammatory bowel disease Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Inflammatory bowel disease Unmet Needs

10. Key Endpoints of Inflammatory bowel disease Treatment

11. Inflammatory bowel disease Marketed Products

12. Inflammatory bowel disease Emerging Therapies

13. Inflammatory bowel disease: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Inflammatory bowel disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Get in touch with our Business executive at Inflammatory Bowel Disease Market Analysis

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/